We evaluated factors that influenced morbidity and mortality in patients undergoing completion pneumonectomy (CP).
INTRODUCTION
Completion pneumonectomy (CP) is resection of the remaining lung tissue after a previous pulmonary resection. It is a technically demanding procedure with high morbidity and mortality compared with standard pneumonectomy and remains a highrisk procedure. Some authors have questioned its role in the light of an alleged high mortality which ranges from 12 to 21% in the largest series [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Morbidity also is high, up to 62.6% in the large experience from Mayo Clinic [11] . Indications for CP include both benign and malignant diseases and are expanding as a result of the rising incidence of lung cancer, increased survival rates after pulmonary resection for lung cancer or infection, more accurate follow-up with multidisciplinary team discussion, expanded indications for sleeve lobectomies and improvements in imaging techniques and perioperative care. Extensive experience is rare, and very few series exceed 50 patients, with around 1000 total patients published in the literature. In a multicentre international study, we reviewed the experience of six highvolume thoracic institutions from three different countries in order to evaluate morbidity and mortality of CP and try to provide an answer to the major questions regarding its specific role.
MATERIALS AND METHODS
From March 1990 to December 2009, 165 patients underwent CP in six international institutions from three different countries (Table 1) . They were collected via a retrospective review of a consecutive series of patients in the participating centres. The initial surgical procedures are shown in Table 2 . Before CP, all patients were carefully restaged by means of a computed tomography (CT) scan of the chest, abdomen and brain and bronchoscopy. In some patients, bone scintigraphy, brain magnetic resonance imaging and positron emission tomography -computed tomography (PET-CT) scan also were performed. Pulmonary function tests were obtained to ascertain the patient pulmonary reserve, and only patients with a predicted postoperative FEV1 of more than 1.0 (or more than 40%) and acceptable cardiac function underwent CP.
Operative mortality was defined as death occurring during the hospitalization period following surgery. Morbidity, in this study, was defined as complications that occurred during the hospitalization period during and after surgery, and included respiratory failure necessitating mechanical ventilation for more than 48 h, acute respiratory distress syndrome, bronchopulmonary artery fistula, bronchopleural fistula (BPF), arrhythmia, renal failure, empyema, pulmonary oedema, myocardial infarction, recurrent nerve palsy, hoarseness, haemorrhage, redo surgery and multiorgan failure.
Statistics
Continuous variables were presented as mean ± SD. Discrete variables between groups were compared using χ 2 -test. Survival analysis was performed by using Kaplan-Meier method, and differences of survival distributions between groups were calculated by log-rank test. A P-value of <0.05 was considered statistically significant.
RESULTS
Indications for CP are shown in Table 3 . The mean interval time between first resection and CP was 47.06 ± 67.5 months (median: 42 months; range: 4-192 months). Intraoperative mortality was 0.6% (1 of 165). Overall operative mortality was 10.3% (17 of 165): 10.5% (16 of 152) in malignant disease and 7.7% (1 of 13) in benign disease. Complications occurred in 55.1% (91 of 165) of patients. Mean volume of operative blood loss per procedure was 724.07 ± 461.9 ml (range: 70-3000 ml). Mean hospital stay was 16.02 ± 16.8 days (range: 3-151 days). Thirteen patients (7.9%) developed BPFs, which were late in all but one patient. Twenty-four patients developed cardiac arrhythmias, five pleural empyema with no fistula and two underwent re-operation for postoperative haemorrhage. CP was performed for malignant disease in 152 (92.1%) and for benign disease in 13 patients (7.9%). A right CP was performed in 99 patients (60.0%) and a left CP in 66 patients (40.0%). The operative approach was thoracotomy in 161 patients (97.6%) and midline sternotomy in 4 patients (2.4%). Intrapericardial ligation of pulmonary vessels was performed in 130 patients (78.8%). Bronchial closure was performed by stapler in 121 (73.4%) cases and by hand suture in 44 (26.6%). Stapled compared with hand closure for the bronchus did not affect the BPF rate (P = 0.4). Hospital stay was divided into three groups: group A (less than 10 days), group B (between 10 and 20 days) and group C (more than 20 days). Malignant diseases showed a statistically significant shorter hospital stay compared with benign diseases, with 51.3% of patients in group A and 33.1% in group B versus 23.1% in group A and 23.1% in group B in the benign disease subset (χ 2 : 11.7; P = 0.002). Patients who underwent stapled bronchial closure showed a statistically significant shorter hospital stay compared with manual closure with 56.8% of patients in group A and 23.7% in group B versus 27.9% in group A and 55.8% in group B in the manual bronchial closure subset (χ 2 : 15.5; P = 0.0004). Twenty-four patients (14.54%) underwent mechanical ventilation for at least one night, of which 16 (66.7%) were right-sided procedures. Histological data are showed in Table 3 . Forty-two patients underwent induction therapy before CP (Table 1) . Adjuvant therapy was performed in 39 patients. With regards to mortality and morbidity, the following variables were considered by using the χ 2 -test: the side of procedure (right versus left), the gender (males versus females), the patients undergoing induction therapy versus those who did not and the surgical approach (thoracotomy versus sternotomy), and no statistical significant relationship was found.
The overall 5-year survival was 37.6%: 70.1% in benign disease (13 patients), 48.9% in squamous cell carcinoma of the lung (63 patients), 23.9% in primary lung adenocarcinoma (62 patients), 50.0% neuroendocrine carcinoma (4 patients of which 1 was grade 1 and 3 were grade 2) and 54.7% (14 patients) in metastatic disease. A statistically significant better survival was observed in patients with squamous cell carcinoma versus adenocarcinoma (P = 0.04) (Figs. 1 and 2 ).
DISCUSSION
CP is a challenging procedure that has high risks in terms of morbidity and mortality. Decision-making in performing CP is difficult especially in the light of literature from two large series published in the 2000s from France and the USA. These studies reported a mortality rate over 20% (Table 4) . Recent advances in operative techniques, anaesthesia and postoperative care have remarkably decreased the morbidity and mortality after surgery for lung cancer.
This multicentre international study presented above is the largest single series dealing with CP. The overall operative mortality rate reported in our paper is 10.3%, a figure which looks reasonable for such an extensive procedure (Table 4) .
A figure which must also be kept in mind is the risk of intraoperative mortality which has been as high as 5.3 and 11.8% in early series by McGovern et al. [10] and Mathisen et al. [1] , respectively. In our series, intraoperative mortality was very low, only 1 in 165, equal to 0.6% (Table 4) .
The morbidity rate has been confirmed to be a major issue of CP, as 91 patients (55.1%) showed at least one major complication.
The incidence of BPF (7.9%) in our series was not affected by the technique of bronchial closure, stapled or hand closure (P = 0.4) and was close to the value reported in the literature which ranges from 7 [11] to 13.3% [2] in the majority of the series.
Side, gender, induction therapy and surgical approach (thoracotomy or midline sternotomy) did not influence mortality and morbidity. Hospital stay was statistically significant longer in patients with benign diseases and in patients who underwent manual closure of the bronchus, an issue which has never been evaluated before.
In our opinion, an intrapericardial approach through midline sternotomy could be an interesting and safe alternative in right cases with hilar tumours. Manoeuvres such as intrapericardial blood vessel ligation, division of the bronchus first, bronchial reinforcement and local application of glues and haemostatic agents were routinely used to avoid perioperative troubles. Our mean volume of blood loss, 724 cm 3 , compares favourably to a recent series from Japan which reported a mean volume of blood loss of 2423 ml [9] . The risk of prolonged mechanical ventilation requires a dedicated respiratory intensive care physician for an uneventful postoperative care. Decisive for the outcome is the careful diagnosis, including the preparation and selection of the patients in order to reduce postoperative complications. PET-CT scan is highly recommended as well as preoperative pathological diagnosis of the pulmonary lesion. Invasive mediastinal staging of suspicious nodes on CT scan is also required to avoid unnecessary procedures in clinical N2 disease and must preferentially be performed with endobronchial ultrasound (EBUS) or endoscopic ultrasound (EUS) and not through mediastinoscopy to avoid dense adhesions from primary surgery. A careful preoperative respiratory and cardiac evaluation is mandatory. A primary resection ensures better tolerance by the cardiopulmonary system of the second procedure, compared with a one-stage pneumonectomy [2] .
The survival data reported in the present series are in line with the literature (Table 4) , even if the survival analysis goes beyond the purpose of the present study. The overall 5-year survival is 37.6%, which becomes much more appealing in some subsets, i.e. benign (70.1%), metastatic patients (54.7%), squamous cell carcinoma (48.9%) compared with adenocarcinoma (23.9%). It should be noted that a significantly better 5-year survival was observed in patients with squamous cell carcinoma versus adenocarcinoma (P = 0.04). Such data takes into consideration the poor prognosis of a recurrent adenocarcinoma compared with recurrent squamous cell carcinoma. The appealing results achieved for resection of pulmonary metastases by means of CP remain under discussion even if a recent paper has shown that extended resections may establish curative benefits [16] . Nevertheless, such an aggressive approach needs further data before a clear recommendation can be made.
With regards to operative mortality and diagnosis, in most series, benign diseases show an increased mortality compared with malignant diseases (Table 4) : in Guginno's series, the operative mortality in benign diseases was 30.8%, in Verhagen's series 25% and in Miller's series 26.3%. In our series, as in Chataigner's series, the operative mortality for benign disease was lower than for malignant diseases (7.7 versus 10.5%).
The strength of the present paper is the compilation of cases from six different institutions and three different countries from Europe and the USA. In our opinion, such diversity could give robustness to the study, providing a general overview of results in a contemporary series of patients undergoing CP. The major bias of the paper is the retrospective study design which is inevitable in such rarely performed procedures.
In summary, CP is a demanding procedure associated with an acceptable operative mortality (10.3%) and a very high morbidity rate (55.1%) which should be performed in high-volume thoracic surgical institutions with large experience in lung surgery and dedicated respiratory intensive care physicians. Side, gender, induction therapy and surgical approach did not influence morbidity and mortality. In some subsets of patients, such as neuroendocrine tumours, metastatic disease and squamous cell carcinomas, the 5-year survival shows the highest survival rate. Careful patient selection is needed taking into account type of resection, previous treatment and comorbidity. PET-CT scan is needed as well as minimally invasive mediastinal staging, mostly by EBUS or EUS in the case of suspicious nodes. A multidisciplinary team decision is always encouraged before undertaking CP.
APPENDIX. CONFERENCE DISCUSSION
Dr A. Maat (Rotterdam, Netherlands): I personally always had in mind the 20% mortality in the Mayo Clinic series, and you have brought it down to 10% with six different hospitals, which is impressive.
Completion pneumonectomy is a very difficult operation, and even in a high-volume centre, it's a rare species, since two of the six centres contributed less than one patient per year in the duration of the study. I saw that almost one out of six patients left the OR intubated and were ventilated at least for the first postoperative night; I personally hate it when a patient leaves the OR with a tube in after lung surgery. Could it have been attributed to the 13 patients with bronchopleural fistula? What measures did you take to prevent patients leaving the OR intubated? Were there measures taken to prevent bronchopleural fistula, like muscle flap coverage?
Dr Cardillo: I agree with you completely. A patient who leaves the OR intubated after lung surgery is a very big problem for everybody. Careful preoperative selection of the patients is key. Patients should be very well evaluated before every kind of lung surgery, especially patients who are undergoing completion pneumonectomy. So I think that careful preoperative selection is vital. There may of course be intraoperative problems. The two major reasons for a patient being intubated are respiratory insufficiency because of a preoperative condition, or an intraoperative problem. So those are the issues.
As regards avoiding bronchopleural fistula, which is a very problematic complication, in most cases we cover the bronchus with viable tissue. You know, we have six institutions and it depends on the personal experience of every surgeon, but, if possible and if needed, viable tissue on the bronchus is very, very welcome.
Dr D. Wood (Seattle, WA, USA): You came to two conclusions that I am concerned about. One is advocating that completion pneumonectomy has benefit for metastatic disease, and you had 14 cases in 6 institutions over a long time period. So these are extremely, extremely, selected patients. They are some very refined subset of metastatic patients that ever get considered for completion pneumonectomy. I think it's almost so specialized that one can hardly draw conclusions from it, being such a rare entity. So I would just caution against representing that this is a feasible therapy in general for patients with metastatic disease.
Second, in one of your conclusion slides, it says that we need intensivists, respiratory intensivists to take care of these patients, yet in our own unit we have cardiothoracic surgeon intensivists that take care of these patients. So I would wonder how you came to the conclusion that we need intensivists other than surgeons to take care of this subset of patients in order to have good outcomes.
Dr Cardillo: Regarding the first question about metastatic disease, I agree with you that maybe it's too much surgery to offer the patient with metastatic disease, but up to now, when we discuss the patient in our multidisciplinary team meeting, I think that oncologists are very keen to do as much as possible for the patient with metastatic disease, provided that the metastatic disease is only in one lung and the patient has a good quality of life. So I think that, of course, it's a question that should be addressed in a better way. At least it is something that we should discuss. It's important that you raised this question because it's a question that we have to discuss with our oncologists. So in our everyday practice, trust me, we discuss what to do with extensive metastatic disease. Completion pneumonectomy can be an option. Of course, maybe it's too much, but it's an option that will be discussed further on.
As regards the role of dedicated intensivists, yes, you are right, we are surgeons and we have to take care of the patients from the beginning as they come in the hospital to the end when they leave the hospital. But in some instances, honestly, to be able to discuss some approaches, some therapy with dedicated intensivists, I think is something that can help those of us who don't have a very great experience with intensive care. I appreciate your question. In my opinion, the surgeons should take care of the patient, but a dedicated intensivist can maybe help some of us.
Dr T. Treasure (London, UK): Doug Wood asked you two very insightful questions. I would like to come back to it because I think you may have missed his point. He wasn't saying that you did the wrong thing or that he contradicts the results. The point he's making is that these patients started off having a primary cancer, which they survived and did well for a while; they had a metastasectomy, which they survived and did well for a while, and they are very highly selected survivors. They don't provide evidence on an intention-to-treat basis. The results are incontrovertibly impressive, but they don't represent a practice policy. I think that's the point.
Dr C. Saldarriaga (Medellin, Colombia): In this series, you had 13 bronchopleural fistulas. How many of these patients had induction therapy and how many died of bronchopleural fistula?
Dr Cardillo: I don't have all of the figures. I don't have the manuscript here, so I don't remember how many of these patients, but there was no relationship between induction therapy and bronchopleural fistula in that subset of patients. And, of course, in the bronchopleural fistula subset, some of the patients were previously treated with radiochemotherapy and in some cases people died because of the fistula.
